||||||||||ADP009 / Alector Characterization of suppressive myeloid cells in solid tumors to refine disease selection in a Phase 1 study of the multi-Siglec inhibitor AL009 (Hall C) - Oct 6, 2022 - Abstract #SITC2022SITC_453; This IHC panel will be utilized to retrospectively explore Siglecs, CD163, and CD68 as predictive biomarkers in an upcoming Phase 1 study. Ethics Approval The human tissue microarrays were procured from a commercial vendor that collect human samples with the following ethical considerations: informed donor consent, IRB/EC approval, fully anonymized, and compliant with current US (HIPAA) International and EU regulations.
||||||||||ADP009 / Alector AL009 is a multi-Siglec inhibitor engineered to bind myeloid cells that enhances innate and adaptive immunity to cancer (Section 38) - Mar 9, 2022 - Abstract #AACR2022AACR_2799; This targeting leads to repolarization of myeloid cells and activates an innate and adaptive anti-cancer response. Pharmacologically relevant doses of AL009 appear well-tolerated in initial studies in non-human primates, supporting further development for entry into clinical studies.